公开(公告)号：AU683316B2

公开(公告)日：1997-11-06

申请号：AU8075694

申请日：1994-10-12

Applicant: UNIV TEXAS ,  PHARMACYCLICS INC

Inventor： SESSLER JONATHAN L ,  HARRIMAN ANTHONY M ,  MILLER RICHARD A ,  MODY TARAK D ,  HEMMI GREGORY W ,  KRAL VLADIMIR A ,  MAGDA DARREN

IPC: A61K31/40 ,  A61K31/407 ,  A61K41/00 ,  A61K47/48 ,  A61K49/00 ,  A61K49/06 ,  A61K49/08 ,  A61K51/00 ,  A61K51/04 ,  A61L2/00 ,  A61P35/02 ,  A61P43/00 ,  B01J31/06 ,  B01J31/16 ,  B01J31/18 ,  C07D487/22 ,  C07H21/00

Abstract: Texaphyrins are provided for use as radiation sensitizers. Advantageous properties of texaphyrins for use as a radiation sensitizer include: i) a low redox potential which allows radiation-induced hydrated electrons to flow to texaphyrin rather than neutralizing hydroxyl radicals, allowing hydroxyl radicals to cause cellular damage, ii) a relatively stable texaphyrin radical that reacts readily to covalently modify neighboring molecules causing further cellular damage, iii) intrinsic biolocalization, and iv) indifference to the presence or absence of O2. These properties allow texaphyrins to be particularly effective for treating the hypoxic areas of solid neoplasms. Methods of treatment for an individual having a neoplasm or atheroma include the use of a texaphyrin as a radiation sensitizer and as an agent for photodynamic tumor therapy, or the use of a texaphyrin for internal and for external ionizing radiation. Novel texaphyrins are provided.

公开(公告)号：NO961436L

公开(公告)日：1996-06-11

申请号：NO961436

申请日：1996-04-11

Applicant: UNIV TEXAS ,  PHARMACYCLICS INC

Inventor： SESSLER JONATHAN L ,  HARRIMAN ANTHONY M ,  MILLER RICHARD A ,  MODY TARAK D ,  HEMMI GREGORY W ,  KRAL VLADIMIR A ,  MAGDA DARREN

IPC: A61K31/40 ,  A61K31/407 ,  A61K41/00 ,  A61K47/48 ,  A61K49/00 ,  A61K49/06 ,  A61K49/08 ,  A61K51/00 ,  A61K51/04 ,  A61L2/00 ,  A61P35/02 ,  A61P43/00 ,  B01J31/06 ,  B01J31/16 ,  B01J31/18 ,  C07D487/22 ,  C07H21/00

Abstract: Texaphyrins are provided for use as radiation sensitizers. Advantageous properties of texaphyrins for use as a radiation sensitizer include: i) a low redox potential which allows radiation-induced hydrated electrons to flow to texaphyrin rather than neutralizing hydroxyl radicals, allowing hydroxyl radicals to cause cellular damage, ii) a relatively stable texaphyrin radical that reacts readily to covalently modify neighboring molecules causing further cellular damage, iii) intrinsic biolocalization, and iv) indifference to the presence or absence of O2. These properties allow texaphyrins to be particularly effective for treating the hypoxic areas of solid neoplasms. Methods of treatment for an individual having a neoplasm or atheroma include the use of a texaphyrin as a radiation sensitizer and as an agent for photodynamic tumor therapy, or the use of a texaphyrin for internal and for external ionizing radiation. Novel texaphyrins are provided.

公开(公告)号：AU1921795A

公开(公告)日：1995-08-29

申请号：AU1921795

申请日：1995-02-15

Applicant: UNIV TEXAS ,  PHARMACYCLICS INC

Inventor： SESSLER JONATHAN L ,  MODY TARAK D ,  HEMMI GREGORY W

IPC: A61K31/40 ,  A61K41/00 ,  A61K47/48 ,  A61K49/00 ,  A61K49/06 ,  A61K49/08 ,  A61K51/00 ,  A61K51/04 ,  A61L2/00 ,  A61P35/00 ,  C07D487/22 ,  C07H21/00

Abstract: Texaphyrin metal complexes having improved functionalization include the addition of electron-donating groups to positions 2, 7, 12, 15, 18 and/or 21 and/or the addition of electron-withdrawing groups to positions 15 and/or 18 of the macrocycle. Electron-donating groups at positions 2, 7, 12, 15, 18 and/or 21 contribute electrons to the aromatic pi system of the macrocycle which stabilizes the metal complex to demetallation and the imine bonds to hydrolysis. The addition of substituents to the 12 and 21 positions of the macrocycle offer steric protection for the imine bonds against possible in vivo enzyme hydrolysis. Electron-withdrawing groups at positions 15 and/or 18 render the macrocycle more readily reduced, i.e. the redox potential is lower and the macrocycle more readily gains an electron to form a radical. Such texaphyrins having a low redox potential and imine bond stabilization are useful in a variety of applications.

公开(公告)号：EA031737B1

公开(公告)日：2019-02-28

申请号：EA201270793

申请日：2011-06-03

Applicant: PHARMACYCLICS INC

Inventor： BUGGY JOSEPH J ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID J ,  MODY TARAK D

IPC: A61K31/519 ,  A61K31/505 ,  A61P35/00 ,  A61P35/02

Abstract: Изобретениеотноситсяк применениюсоединения, имеющегоформулудлялечениярецидивирующегоилирезистентногохроническоголимфоцитарноголейкоза (ХЛЛ), рецидивирующейилирезистентноймелкоклеточнойлимфоцитарнойлимфомы (МЛЛ) илимфомыизклетокмантийнойзоны.

公开(公告)号：ZA201400012B

公开(公告)日：2016-01-27

申请号：ZA201400012

申请日：2014-01-06

Applicant: PHARMACYCLICS INC

Inventor： MODY TARAK D ,  LOURY DAVID J ,  CHEN WEI

公开(公告)号：SG10201506776RA

公开(公告)日：2015-10-29

申请号：SG10201506776R

申请日：2010-10-12

Applicant: PHARMACYCLICS INC

Inventor： CHEN WEI ,  LOURY DAVID J ,  MODY TARAK D ,  VERNER ERIK ,  SMYTH MARK STEPHEN ,  LUO WENCHEN

公开(公告)号：UA107707C2

公开(公告)日：2015-02-10

申请号：UAA201214953

申请日：2011-06-03

Applicant: PHARMACYCLICS INC

Inventor： BUGGY JOSEPH J ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID J ,  MODY TARAK D

IPC: A61K31/519 ,  A61K31/505 ,  A61P35/02

公开(公告)号：AU2012283775A1

公开(公告)日：2014-01-23

申请号：AU2012283775

申请日：2012-07-13

Applicant: PHARMACYCLICS INC ,  WANG LONGCHENG

Inventor： CHEN WEI ,  LOURY DAVID J ,  MODY TARAK D

IPC: C07D473/32 ,  A61K31/433 ,  A61K31/52 ,  A61P17/00 ,  A61P29/00 ,  C07D473/34

Abstract: Described herein are kinase inhibitor compounds, methods for synthesizing such inhibitors, and methods for using such inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate inhibitor of a protein, including a kinase.

公开(公告)号：CR20120244A

公开(公告)日：2013-01-03

申请号：CR20120244

申请日：2012-05-11

Applicant: PHARMACYCLICS INC

Inventor： CHEN WEI ,  LOURY DAVID J ,  MODY TARAK D ,  VERNER ERIK ,  SMYTH MARK STEPHEN ,  LUO WENCHEN

IPC: C07D487/04 ,  A61K31/519 ,  A61P19/02 ,  A61P19/10 ,  C07D401/04 ,  C07D401/14

Abstract: Se describen aquí compuestos inhibidores de quinasa, métodos para sintetizar tales inhibidores y métodos para utilizar tales inhibidores en el tratamiento de enfermedades. Se describen aquí adicionalmente métodos, ensayos y sistemas para determinar un inhibidor apropiado de una proteína, incluyendo una quinasa.

公开(公告)号：MX2012004258A

公开(公告)日：2012-05-29

申请号：MX2012004258

申请日：2010-10-12

Applicant: PHARMACYCLICS INC

Inventor： LOURY DAVID J ,  CHEN WEI ,  VERNER ERIK ,  LOURY DAVID J ,  MODY TARAK D ,  SMYTH MARK STEPHEN ,  LUO WENCHEN

IPC: A61F2/24 ,  A61K31/519 ,  A61P19/02 ,  A61P19/10 ,  C07C6/02 ,  C07D401/04 ,  C07D401/14 ,  C07D487/04

Abstract: Se describen aquí compuestos inhibidores de quinasa, métodos para sintetizar tales inhibidores y métodos para utilizar tales inhibidores en el tratamiento de enfermedades. Se describen aquí adicionalmente métodos, ensayos y sistemas para determinar un inhibidor apropiado de una proteína, incluyendo una quinasa.